Comparative Pharmacology
Head-to-head clinical analysis: MINOXIDIL FOR WOMEN versus THEROXIDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINOXIDIL FOR WOMEN versus THEROXIDIL.
MINOXIDIL (FOR WOMEN) vs THEROXIDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minoxidil is a potassium channel opener. It activates ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arterioles, causing peripheral vasodilation and reduced blood pressure. For hair growth, the exact mechanism is unclear but involves increased cutaneous blood flow, stimulation of hair follicle proliferation via direct effects on dermal papilla cells, and prolongation of the anagen phase.
Theroxidil is a vasodilator that acts by opening potassium channels in vascular smooth muscle, leading to hyperpolarization and relaxation. It also inhibits platelet aggregation and reduces peripheral vascular resistance.
Topical: 2% or 5% solution, 1 mL applied to the scalp twice daily (morning and evening).
5 mg orally once daily, increased to 10 mg after 4 weeks as tolerated.
None Documented
None Documented
Terminal elimination half-life: approximately 4.2 hours in patients with normal renal function; may extend to 24+ hours in renal impairment.
Terminal elimination half-life 24-30 hours; steady-state reached after 4-5 days; clinically significant for once-daily dosing
Primarily renal (90% as unchanged drug and metabolites; 10% via feces via biliary elimination).
Approximately 60% renal (15% unchanged, 45% as glucuronide metabolites), 40% fecal/biliary as metabolites
Category A/B
Category C
Vasodilator / Hair Growth Stimulant
Vasodilator